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in response to   -adrenergic receptor signaling. In addition, 
adipose tissue is a well-characterized endocrine organ that 
secretes hormones and regulates lipid homeostasis across 
the body ( 2 ). Adipogenesis, the process of adipocyte dif-
ferentiation, was initially thought not to proceed beyond 
the formation of adipose tissue, i.e., after the prenatal and 
early postnatal period. However, data have shown that new 
adipocytes can be formed during adulthood ( 3 ). 
 Dietary fat has been correlated with increased adipocyte 
number (hyperplasia) and size (hypertrophy) ( 4 ). How-
ever, it is now apparent that this is a simplistic view, as fats 
have different effects on adiposity depending on their na-
ture and properties. The role of arachidonic acid (AA), a 
major n-6 PUFA, on obesity is controversial from studies 
using both in vivo and in vitro models ( 5–10 ). However, it 
has been demonstrated that the protein/carbohydrate ra-
tio in the diet can determine the role of AA on adiposity 
( 11 ). AA can be metabolized to a diverse group of metabo-
lites, depending on the presence and activity of catalyzing 
enzymes. Prostaglandins (PGs), the products of AA gener-
ated by cyclooxygenases (COXs), have opposing effects on 
adipogenesis, as prostacyclin (PGI 2 ) and 15-deoxy-  
12,14 
prostaglandin J 2 (PGJ 2 ) promote ( 12–15 ) and prostaglan-
din E 2 (PGE 2 ) and prostaglandin F 2   (PGF 2   ) inhibit adi-
pocyte differentiation ( 16–18 ). 
 Due to the important role of lipids in adipocytes, it is not 
surprising that fatty acid protein 4 (FABP4 or aP2) consti-
tutes 5% of the total protein of an adipocyte ( 19 ). aP2 is a 
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 Adipocytes are the primary site for fat storage with 90% 
of the adipocytes’ cytoplasm containing a large lipid drop-
let ( 1 ). Apart from their role in fat storage, adipocytes are 
the major players in handling the lipid distribution across 
the body. Adipocytes can synthesize and take up lipids by 
sensing insulin, and can also hydrolyze and secrete lipids 
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antibiotics (Sigma-Aldrich) at 37°C in 5% CO 2 . For the short-
term experiments, 48 h after reaching confl uence (day 0), cells 
were treated with a differentiation cocktail (MDI) of 0.5 mM me-
thylisobutylxanthine (Sigma-Aldrich), 250 nM dexamethasone 
(Sigma-Aldrich), and 170 nM insulin (Sigma-Aldrich) in the 
presence of AA or BSA (vehicle) for 24 h. For the long-term ex-
periments, cells were cultured and treated the same as the short-
term experiments until 24 h, when the AA or BSA was withdrawn. 
The MDI cocktail was then kept for an additional 24 h (day 2), 
when it was replaced by culture medium containing insulin (170 
nM) until the end of the differentiation program (day 10). The 
medium was replenished every 2 days. For ERK experiments, 2 
day postconfl uent cells were serum-starved overnight and then 
assayed as described. For the pretreatment experiments, 2 day 
postconfl uent cells were preincubated with the respective inhibi-
tors for 30 min (see the Results section) followed by AA or BSA 
treatments for 24 h in the presence of MDI. 
 For siRNA-mediated FP receptor (siFP) and Fra-1 (siFra-1) 
knockdown, 80–90% confluent 3T3-L1 cells were transfected 
with siRNA (ON-TARGETplus SMARTpool, mouse FOSL1 or 
mouse PTGFR, Dharmacon) or scrambled sequences (siControl) 
with Dharmafect 3 (Dharmacon), according to the manufacturer’s 
instructions. The cells were treated on the third day after trans-
fection and were either harvested after 24 h or retransfected and 
harvested at the end of the differentiation program. 
 Preparation of albumin-bound fatty acid 
 Stock solution of AA (10 mM) (Cayman Chemical) was pre-
pared by diluting the FFA in ethanol and precipitating it with the 
addition of NaOH (fi nal concentration of 0.25 M). The precipi-
tated sodium salt was then evaporated under nitrogen gas, recon-
stituted with 0.9% (w/v) NaCl, and stirred at room temperature 
for 10 min with fatty acid-free BSA (Sigma-Aldrich) in 0.15 M 
NaCl. The solution was stored in multiple aliquots at   20°C and 
protected from light in tubes evacuated under nitrogen gas. Con-
trol solution containing fatty acid-free BSA was similarly pre-
pared. The FFA/BSA molar ratio was 4:1 ( 38 ). All AA treatments 
contained 0.22 mM   -tocopherol (Sigma-Aldrich) to prevent 
lipid peroxidation ( 39 ). 
 Western blotting 
 Cells were lysed in ice-cold lysis buffer containing 1% Triton-
X, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5 mM EDTA, 
1 mM PMSF (Sigma-Aldrich), 1× protease inhibitor cocktail 
(Roche), and 1× phosphatase inhibitor cocktail (Sigma-Aldrich). 
Protein concentration was determined using the BCA TM protein 
assay kit (Pierce). Equal amounts of protein were resolved by SDS-
PAGE and electro-transferred onto a polyvinyl difl uoride mem-
brane (Millipore). Blots were blocked in 5% nonfat dry milk or 
5% BSA in 1× TBS-T (TBS with 0.1% TWEEN 20) . Primary 
antibody was applied in the same buffer at a dilution of 1:1,000. 
Primary antibodies were purchased either from Cell Signaling 
Technology [phospho-p44/42 (9101) and total ERK (9102)], 
Millipore [GAPDH (MAB374)], or Santa Cruz Biotechnology 
[Fra-1 (sc-605)]. Horseradish peroxidase-conjugated secondary 
antibodies (Invitrogen) were applied in a dilution of 1:5,000. 
Finally, the signal was detected using enhanced chemiluminescence 
substrates (Pierce) following the manufacturer’s instructions and 
the light emission was captured and visualized by exposing the 
blot to fi lm. Densitometry was carried out by analyzing Western 
blot images with ImageJ software. 
 Quantitative RT-PCR 
 Total RNA was isolated from cells using TRI Reagent (Sigma-
Aldrich) and reverse transcribed to cDNA using M-MLV reverse 
lipid chaperone binding hydrophobic ligands that facili-
tates the transport of lipids to specifi c compartments in the 
cell ( 20 ), interacts with various players of the regulatory 
mechanisms of adipocyte function ( 21 ), and translocates to 
the nucleus affecting gene expression ( 22 ). However, the 
function of aP2 is still poorly understood, as aP2 knockout 
mice show insulin sensitivity in the context of both dietary 
and genetic obesity, but not in lean mice ( 23 ). The expres-
sion of aP2 is induced during adipocyte differentiation, as it 
is transcriptionally controlled by the master regulator of 
adipogenesis, PPAR  ( 24 ). PPAR  is activated by natural 
(fatty acids) or synthetic agonists (such as thiazolidinedio-
nes), which also lead to aP2 upregulation ( 13–15, 25, 26 ). 
 Activator-protein 1 (AP-1) transcription factors have 
been implicated in both adipogenesis ( 27 ) and regulation 
of aP2 expression ( 28 ). The AP-1 family consists of the Fos 
[Fos-related antigen (Fra)-1, c-Fos, FosB, and Fra-2] and Jun 
proteins (c-Jun, JunB, and JunD), which can heterodimer-
ize ( 29 ). Fra-1 is an AP-1 factor that is of particular interest 
in adipogenesis, as Fra-1 transgenic mice have severe lipo-
dystrophy with Fra-1 inhibiting CCAAT/enhancer binding 
protein   (C/EBP  ) expression ( 30 ). It is induced early in 
the adipocyte differentiation program ( 31 ) and its expres-
sion is enhanced by PPAR  agonists ( 32 ), fatty acids ( 33 ), 
mitogens ( 34 ), and insulin ( 35 ). Little is known about Fra-1 
target genes in preadipocytes and its mode of action, as it 
could be both an activator and a repressor ( 36, 37 ). 
 As AA is a major n-6 PUFA and a signifi cant signaling 
molecule abundant in the Western diet, it is important to 
understand how it regulates adiposity through the process 
of adipocyte differentiation. Hence, the current study 
aimed to elucidate the effects of AA at the early stages of 
adipogenesis and delineate the events initiated by AA to 
program the differentiation ability of preadipocytes. We 
demonstrate that AA, after 24 h of treatment, is metabo-
lized by COXs to generate PGF 2   , which binds to its mem-
brane G protein-coupled receptor (GPCR), the FP receptor, 
and in turn induces the calcium/protein kinase C (PKC)/
ERK signaling pathway that causes the upregulation of aP2 
and Fra-1 expression. We also show that the inhibition of 
terminal differentiation by AA present at the early stages of 
adipogenesis is Fra-1-dependent, as Fra-1 knockdown could 
rescue the inhibitory effect of AA on differentiation. 
 MATERIALS AND METHODS 
 Reagents 
 Carbaprostacyclin (cPGI 2 ), AL 8810, baicalein, and 17-octadecynoic 
acid (17-ODYA) were purchased from Cayman Chemical. 
15-Deoxy-  12,14 PGJ 2 , PGE 2 , PGF 2   , SC-560, SC-236, and indo-
methacin were all purchased from Sigma-Aldrich. PD98059, 
U0126, and GF109203X were obtained from Enzo Life Sciences 
and BAPTA-AM from Tocris Bioscience. 
 Cell culture 
 3T3-L1 cells were maintained in subconfl uent culture in 
DMEM containing 4.5 g/l glucose and L-glutamine (Invitrogen) 
supplemented with 10% newborn calf serum (Invitrogen) and 
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been used in prior in vitro studies ( 33, 40 ). Initially, we 
observed that lipid droplet formation was increased pro-
portionally with the AA concentration ( Fig. 1A ). To exam-
ine whether AA promotes the early terminal differentiation 
of preadipocytes, the expression of late gene markers of 
differentiation was assessed, such as aP2, PPAR  2, C/
EBP  , and FAS, following 24 h of treatment with AA. aP2 
was the only late differentiation gene marker that was up-
regulated by AA in a dose-dependent manner ( Fig. 1B ). A 
signifi cant, but not as dramatic, increase in aP2 levels was 
also observed following 24 h treatment with AA in the ab-
sence of MDI ( Fig. 1C ). To examine whether the effect of 
AA on aP2 expression occurs earlier than 24 h, time-course 
experiments were performed with 100   M AA in the pres-
ence of MDI. We observed that the aP2 mRNA expression 
was signifi cantly upregulated only after 24 h of AA treat-
ment, but not at earlier time points ( Fig. 1D ). Our results 
suggest that the upregulation of aP2 expression by AA was 
a gene-specifi c effect rather than an effect on the differen-
tiation program. 
 PGF 2   mediates the effect of AA on aP2 expression 
 AA is a substrate of enzymes in the eicosanoid pathway 
[COXs, lipoxygenases (LOXs), and P450 epoxygenases] 
producing a variety of metabolites. To examine whether 
these derivatives of AA have a role in the regulation of aP2 
expression, 3T3-L1 cells were pretreated with either indo-
methacin (a general COX inhibitor), a selective COX-2 
(SC-236) and a COX-1 inhibitor (SC-560), baicalein (a 
12/15 LOX inhibitor), or 17-ODYA (a cytochrome P450 
epoxygenase inhibitor). Indomethacin and the selective 
COX inhibitors signifi cantly blocked the AA-dependent 
induction of aP2 mRNA levels ( Fig. 2A ) and the expres-
sion of both COX-1 and -2 was upregulated by AA in a 
dose-dependent manner (supplementary Fig. I). However, 
the effect of AA was not blocked by the LOX or epoxygen-
ase inhibitors ( Fig. 2B ), indicating that PGs mediate the 
effect of AA on aP2 expression. 
 To identify which PGs mediate the increase in aP2 expres-
sion by AA, a dose response experiment was carried out 
treating 3T3-L1 cells with either carbaprostacyclin (cPGI 2 ; 
an analog of PGI 2 ), PGF 2   , PGE 2 , or 15-deoxy-  
12,14 PGJ 2 for 
24 h in the presence of MDI. PGF 2   had a similar effect to 
AA on aP2 expression ( Fig. 2C , red line), where at the low-
est concentration (1 nM) tested, it was able to upregulate 
aP2 mRNA levels almost 100-fold. PGE 2 had a promoting 
effect on aP2 expression at 100 nM (30-fold) and cPGI 2 at 
1   M (40-fold) ( Fig. 2C ). However, 15-deoxy-  12,14 PGJ 2 , 
which is a direct PPAR  ligand ( 13–15 ), did not have a sig-
nifi cant effect at any of the doses tested ( Fig. 2C ). To further 
examine whether PGF 2   mimics the effect of AA, a time-
course experiment was performed treating 3T3-L1 cells 
with PGF 2   (10 nM) over the course of 24 h. PGF 2   signifi -
cantly induced aP2 mRNA expression after 12 h and 24 h of 
treatment ( Fig. 2D ), suggesting that it mediates the AA-
dependent upregulation of aP2 expression. As both PGE 2 
and PGI 2 could upregulate aP2 expression ( Fig. 2C ), pre-
adipocytes were pretreated with an EP4 selective antagonist 
transcriptase (Invitrogen), following the manufacturer’s in structions. 
Real-time RT PCR was performed on a 7900HT Fast real-time 
PCR system (Applied Biosystems) using SYBR® Green JumpStart™ 
Taq ReadyMix™ (Sigma-Aldrich). The primers used for real-time 
RT-PCR were: aP2, forward (Fw) 5 ′ -ACACCGAGATTTCC TT-
CAAACTG-3 ′ and reverse (Rv) 5 ′ -CCATCTAGGGTTATGATGC-
TCTTCA-3 ′ ; PPAR  2, Fw 5 ′ -TGGG TGAAACTCTGG GA GA TTC-3 ′ 
and Rv 5 ′ -AGAGGTCCACAGAG CTGATTCC-3 ′ ; c/EBP  , Fw 
5 ′ -TGGAGTTGACCAGTGACA ATGAC-3 ′ and Rv 5 ′ -CAGTT CA-
CG GCTCAGCTGTTC-3 ′ ; FAS, Fw 5 ′ -TGCGGAAA CTTCA GG-
AAATGT-3 ′ and Rv 5 ′ -AGAGACGTGTCACTCCTGGACTT-3 ′ ; 
Fra-1, Fw 5 ′ -CGCAAGCTCAGGCA CAGA-3 ′ and Rv 5 ′ -AATGA-
GGCTGCACCATCCA-3 ′ ; FP receptor, Fw 5 ′ -TTC A GCT CCT-
GGCCATAATGT-3 ′ and Rv 5 ′ -AAAAAGTGTCGTTTCACAGG-
T CACT-3 ′ ; and L19, Fw 5 ′ -GGAAA AAGA AGG TCT GG TTG GA-3 ′ 
and Rv 5 ′ -TGATCTGCTGACGGGAGTTG-3 ′ . 
 Oil Red O staining 
 3T3-L1 cells were stained with Oil Red O (Sigma-Aldrich). The 
culture medium was removed and the cells were washed with 
PBS. Cells were then fi xed with 4% paraformaldehyde in PBS for 
15 min at room temperature. The fi xative was discarded and the 
cells were washed with PBS. Oil Red O (0.15%. w/v) in 60% iso-
propanol was applied for 1 h at room temperature. The cells 
were then rinsed with 60% isopropanol and PBS. Stained lipid 
droplets were visualized under light microscopy. 
 Calcium mobilization assay 
 Two day postconfl uent 3T3-L1 cells were assayed for calcium 
mobilization using the Fluo-4 Direct™ calcium assay kit (Invitro-
gen). On the day of the assay, the dye was prepared according to 
the manufacturer’s instructions. Briefl y, 2× calcium sensitive 
Fluo-4 Direct buffer was mixed with the same volume of differen-
tiation cocktail (MDI) and cells were incubated for 30 min in an 
incubator (5% CO 2 at 37°C). The cells were then incubated for 
an additional 30 min at room temperature. Plates were then 
placed for live cell imaging on an SP5 confocal microscope 
(Leica) using the LAS-AF program. Dishes were left for 1 min to 
gain a basal value before being applied with AA (10   M) for 10 –
 15 min. The data were exported from the program as values 
based on the fl uorescence emitted during the experiment, with 
the basal average intensity from the fi rst 1 min subtracted. 
 Statistical analysis 
 Relative mRNA levels of target genes were normalized to L19 
expression and the effects of different treatments were expressed 
as fold changes to the equivalent control treatments. Results were 
analyzed using the Student’s  t -test.  P values lower than 0.05 were 
considered statistically signifi cant. 
 RESULTS 
 Short-term treatment with AA induces aP2 expression 
in preadipocytes 
 To test whether AA affects gene expression at the early 
stages of differentiation, 3T3-L1 cells were treated with in-
creasing doses of AA (10   M, 100   M, and 1 mM) for the 
fi rst 24 h of differentiation in the presence of standard 
differentiation cocktail (MDI). These doses were selected 
because fatty acids can be found in the plasma of fed or 
fasted mice between a range of 0.1 to 1.2 mM and have 
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 To further confi rm that PGF 2   is the metabolite mediat-
ing aP2 expression by AA, we blocked the signaling initi-
ated by PGF 2   binding to its membrane GPCR receptor, 
the FP receptor. 3T3-L1 cells were either pretreated with 
the FP receptor antagonist (AL 8810, 10   M) or depleted 
of the FP receptor by a targeting siRNA (siFP) prior to AA 
treatment ( Fig. 2E, F ). The induction of aP2 expression by 
AA was signifi cantly blocked in the presence of AL 8810 
(L-161,982, 10   M) or a prostacyclin receptor (IP)-selective 
antagonist (CAY10441, 10   M) ( Fig. 2E ) prior to AA treat-
ment. These antagonists were unable to block the effect of 
AA on aP2 expression, suggesting that these PGs are not 
mediating the effects of AA ( Fig. 2E ). The weaker effects of 
PGE 2 and cPGI 2 on aP2 expression ( Fig. 2C ) could be via 
the known ability of these PGs to bind weakly to the FP re-
ceptor ( K i of 100 nM and 1,200 nM, respectively) ( 41 ). 
 Fig.  1. AA induces the expression of aP2 after 24 h 
of treatment in 3T3-L1 cells. A: Oil Red O stain-
ing of 2 day postconfl uent 3T3-L1 cells (day 0) upon 
AA treatment (10   M, 100   M, and 1 mM) or fatty 
acid-free BSA (vehicle for AA) for 24 h. Cells were 
captured under a light microscope using 20× mag-
nifi cation. B: 3T3-L1 cells (day 0) were incubated 
for 24 h with BSA vehicle (set as 1, dashed line) or 
AA (10   M, 100   M, and 1 mM) in the presence of 
MDI. Total RNA was harvested and RT-PCR was 
performed. Mean values are shown of n = 3 and er-
ror bars represent ±SEM. Statistical signifi cance was 
determined by a Student’s  t -test (two-tailed). ** P < 
0.01, *** P < 0.001. C: 3T3-L1 cells (day 0) were 
treated with AA in the presence or absence of MDI 
for 24 h. A Student’s  t -test was performed for the 
BSA control and AA-treated for each condition and 
between AA-treated in different conditions. Error 
bars represent ±SEM. * P < 0.05, ** P < 0.01, and 
*** P < 0.001. D: 3T3-L1 cells (day 0) were treated 
with 100   M AA in the presence of MDI and total 
RNA was prepared at the indicated time points. 
Data are presented as mean ± SEM based on tripli-
cate determinations. A Student’s  t -test was performed 
for the 24 h time point between the vehicle-treated 
and the AA-treated. *** P < 0.001. 
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10   M AA induced a rapid and robust increase in intracel-
lular calcium ( Fig. 3A , upper panel). This effect was PG-
mediated, as pretreatment with indomethacin completely 
blocked the mobilization of calcium stores ( Fig. 3A , mid-
dle panel). Finally, addition of the FP receptor antagonist 
(AL 8810, 10   M) was able to block the effect of AA on the 
intracellular calcium levels, confi rming that the effect of 
AA on calcium increase was FP-mediated ( Fig. 3A , lower 
panel). 
 To address whether calcium is required for the AA-
induced expression of aP2 expression, 3T3-L1 cells were 
pretreated with a membrane-permeate calcium chelator 
(BAPTA-AM, 30   M) prior to AA. BAPTA-AM signifi cantly 
blocked the upregulation of aP2 expression by AA ( Fig. 3B ). 
Finally, it is known that calcium ions, in conjunction with 
( Fig. 2E ) and reduced by 50% in the presence of siFP 
when the FP receptor mRNA levels were reduced around 
80% ( Fig. 2F ). Overall, these results confi rm that PGF 2   , 
via its membrane FP receptor, mediates AA-induced in-
crease in aP2 expression early in differentiation. 
 PGF 2   signaling pathway regulates aP2 expression 
 The FP receptor is coupled to the G  q/11 family of 
G proteins, which activates the phospholipase C/phos-
phoinositide signaling pathway leading to mobilization of 
calcium from intracellular stores ( 42 ). Hence, calcium 
mobilization studies were performed to determine whether 
AA activates a calcium signaling pathway via the FP recep-
tor. Two days postconfl uent 3T3-L1 cells were loaded with 
the calcium dye Fluo-4 for live cell imaging. Addition of 
 Fig.  2. PGF 2   mediates the effect of AA on aP2 expression in 3T3-L1 cells. 3T3-L1 cells (day 0) were pretreated with indomethacin 
(10   M), SC-236 (10   M), and SC-560 (10   M) (A) and baicalein (10   M) or 17-ODYA (10   M) (B) for 30 min prior to AA (100   M) treat-
ment for 24 h in the presence of MDI. Total RNA was isolated and RT-PCR was performed. C: 3T3-L1 cells (day 0) were treated with 1 nM, 
10 nM, 100 nM, or 1   M of PGF 2   , PGE 2 , cPGI 2 , and 15-deoxy-  
12,14 PGJ 2 for 24 h in the presence of MDI. The red line is the PGF 2   treat-
ment. D: 3T3-L1 cells (day 0) were treated with PGF 2   (10 nM) in the presence of MDI for 24 h. E: 3T3-L1 cells (day 0) were pretreated with 
AL 8810 (10   M), L-161,982 (10   M), or CAY10441 (10   M) for 30 min prior to 100   M AA treatment for 24 h. F: Eighty percent confl uent 
3T3-L1 cells were transfected with a nontargeting control siRNA (siControl) or siRNA targeting the FP receptor (siFP). On the third day 
after transfection, cells were treated with 100   M AA for 24 h in the presence of MDI. RT-PCR was conducted for aP2 mRNA and FP recep-
tor transcripts. Data are presented as mean ± SEM of n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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that AA activates a calcium/PKC pathway via the FP recep-
tor that activates aP2 gene expression ( Fig. 3C ). 
 As both AA and PGF 2   are known to activate ERK signal-
ing in differentiating cells ( 43, 44 ), we assessed whether 
AA-induced aP2 expression requires ERK activation. We 
fi rst determined the temporal profi le of ERK activation by 
AA in preadipocytes. A time-course experiment (0–60 
min) was performed treating 3T3-L1 cells with AA (10   M). 
AA activated ERK following 5 min of treatment, which was 
decreased to basal levels following 15 min of AA treatment 
( Fig. 4A ). 
 As shown in  Fig. 2 , the effect of AA on aP2 expression was 
blocked by COX inhibitors, indicating a role for PG pro-
duction. To address whether AA-induced ERK activation is 
PG-mediated, 3T3-L1 cells were pretreated with indometh-
acin for 30 min and then stimulated for 5 min with AA. 
Indomethacin completely blocked ERK activation by 
AA, indicating that this signaling pathway is PG dependent 
( Fig. 4B ). To investigate whether PGF 2   mediates the AA-
dependent activation of ERK, 3T3-L1 cells were pretreated 
with the FP antagonist, AL 8810 (10   M), for 30 min prior 
to the addition of AA (10   M, 5 min) ( Fig. 4C , upper 
panel). Cells were also treated with PGF 2   (10 nM) in the 
presence or absence of AL 8810 (10   M) as a positive con-
trol ( Fig. 4C , lower panel). AL 8810 could signifi cantly 
block the phosphorylation of ERK by AA, indicating that 
PGF 2   is the PG-activating ERK when cells are challenged 
with AA ( Fig. 4C ). It should be noted that the PGF 2   con-
centration able to activate ERK was 1,000 times lower than 
the concentration of AA able to achieve the same activation. 
The high concentration of AA required to activate ERK in-
dicates that a metabolite of AA, rather than AA itself, medi-
ates this effect. In addition, BAPTA-AM signifi cantly blocked 
AA-mediated ERK activation, indicating that calcium signal-
ing is required for AA-mediated ERK activation ( Fig. 4D ). 
 Finally, preadipocytes were pretreated with a mitogen-
activated protein kinase kinase (MEK) inhibitor (PD98059, 
10   M) before the exposure to AA for 24 h in the presence 
of MDI. PD98059 signifi cantly blocked the AA-mediated 
upregulation of aP2 mRNA expression ( Fig. 4E ), indicat-
ing that ERK signaling activated by AA is required for the 
regulation of aP2 expression. 
 AA upregulates Fra-1 expression through PGF 2   signaling 
 The ERK pathway has been reported to regulate Fra-1 
expression at both a transcriptional and posttranslational 
level ( 45 ). This observation, along with the fi nding that 
Fra-1 is expressed early in adipocyte differentiation ( 31 ) 
and is induced by fatty acids ( 33 ), led us to assess whether 
AA regulates Fra-1 expression. 3T3-L1 cells were treated 
with increasing doses of AA in the presence of MDI and 
harvested after 24 h of treatment. Fra-1 mRNA levels 
increased proportionally with increasing doses of AA. 
Protein levels also increased after 24 h of AA treatment 
(100   M) ( Fig. 5A ). To confi rm that Fra-1 expression is 
regulated by AA via the same pathway as aP2, 3T3-L1 cells 
were pretreated with indomethacin before treatment with 
AA, and Fra-1 protein levels were assessed. Not only was Fra-1 
upregulation by AA blocked by the general COX inhibitor, 
diacylglycerol, activate PKC ( 42 ). Hence, in order to ex-
amine whether PKC is involved in the regulation of aP2 
expression by AA, a PKC inhibitor (GF109203X, 10   M) 
was added to 3T3-L1 cells prior to treatment with AA for 
24 h. The induction of aP2 expression was completely 
blocked by preincubation with the PKC inhibitor, suggesting 
 Fig.  3. The calcium and PKC signaling pathway mediates 
the effect of AA on aP2 expression. A: 3T3-L1 cells (day 0) were 
loaded with calcium-sensitive Fluo-4 before stimulation with 
10   M AA (red line) or BSA-vehicle (black line), and calcium 
mobilization was determined by live cell imaging for 10–15 min 
(top panel). Cells were pretreated with indomethacin (10   M) 
(middle panel) or AL 8810 (10   M) (lower panel) for 30 min 
before stimulation with AA (10   M). A representative experi-
ment from three independent experiments is shown. B, C: 3T3-
L1 cells (day 0) were pretreated with BAPTA-AM (30   M) or 
GF109203X (10   M), as indicated, for 30 min prior to 100   M 
AA treatment for 24 h. Total RNA was extracted and subjected to 
RT-PCR for aP2 mRNA transcript. Data are presented as mean ± 
SEM of n = 3. *** P < 0.001. 
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blocked by both the FP antagonist and the siFP, demon-
strating that AA-induced Fra-1 expression is mediated by 
PGF 2   via the FP receptor. ( Fig. 5D, E ). 
 To further investigate the signaling pathway activated by 
AA that upregulates Fra-1 expression, 3T3-L1 cells were 
pretreated either with a PKC inhibitor (GF109203X, 10   M) 
but PGF 2   was also able to mimic the effect of AA on Fra-1 
mRNA and protein expression ( Fig. 5B, C ). To determine 
whether the effect of AA on Fra-1 expression is FP receptor-
mediated, 3T3-L1 cells were either pretreated with AL 
8810 (10   M) or depleted of the FP receptor using a target-
ing siRNA (siFP). Fra-1 upregulation by AA was completely 
 Fig.  4. ERK kinase mediates the effect of AA on aP2 expression. A: 3T3-L1 cells (day 0) were serum starved 
overnight and treated with 10   M AA for the indicated time points. Western blotting was performed using 
antibodies against phosphor-ERK, total ERK, and GAPDH . The graph shows the densitometric analysis. B: 
Western blot of phosphor-ERK and total ERK of serum-starved cells pretreated with indomethacin (1   M) 
for 30 min prior to AA (10   M) stimulation for 5 min. C: As above, but cells were pretreated with AL 8810 
(10   M) prior to AA (10   M) (top panel) and PGF 2   (10 nM) (bottom panel), or with BAPTA-AM (10   M) 
prior to AA (10   M) (D). E: Cells were pretreated with PD98059 (10   M) for 30 min prior to AA (100   M) 
treatment for 24 h in the presence of MDI. aP2 mRNA levels are presented as fold change of the vehicle 
control from n = 3. Error bars represent ±SEM. * P < 0.05. Densitometry was performed of three independent 
blots normalizing the relative intensity of phosphor-ERK to the corresponding total ERK. * P < 0.05. 
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PPAR  2, and C/EBP  , at day 10 was much lower in the 
AA-treated cells compared with the vehicle control-treated 
cells for all doses tested ( Fig. 6A ). The inhibitory effect of 
AA was maximal when present early in the differentiation 
(during the fi rst 2 days) in comparison to when it was pres-
ent during later stages (after the fi rst 2 days) (data not 
shown). It has to be noted that the aP2 expression was 
downregulated to an extent similar to the other differen-
tiation markers tested, indicating that the effect of AA is 
on the differentiation program and not on the expression 
of specifi c genes (in contrast with the aP2-specifi c effect 
after 24 h of treatment,  Fig. 1 ). Finally, treatment with 
PGF 2   for the fi rst 24 h of differentiation could also inhibit 
differentiation ( Fig. 6B ). 
 Fra-1 expression was increased upon AA treatment at 
the fi rst stages of differentiation ( Fig. 5A ). Thus, it was 
or a MEK 1/2 inhibitor (U0126, 10   M) prior to a 24 h AA 
treatment (100   M). Both inhibitors signifi cantly blocked 
the effect of AA on Fra-1 protein levels, suggesting a role 
for both PKC and ERK pathways in Fra-1 upregulation by 
AA ( Fig. 5F, G ). 
 Short-term AA treatment of preadipocytes inhibits their 
differentiation potential via Fra-1 
 We addressed whether the downstream role of AA-
mediated changes in gene expression at the early stages of 
differentiation is to impact the subsequent differentiation 
potential of preadipocytes. For this, cells were treated with 
increasing doses of AA for the fi rst 24 h of differentiation, 
then AA was withdrawn and the standard differentiation 
protocol was followed until day 10 when cells were harvested. 
The expression of three late differentiation markers, aP2, 
 Fig.  5. AA induces the expression of Fra-1 after 24 h of treatment in 3T3-L1 cells. A: 3T3-L1 cells (day 0) 
were treated with increasing doses of AA (10   M, 100   M, or 1 mM) for 24 h in the presence of MDI. Total 
RNA (left panel) or total cell lysates (right panel, 100   M) were isolated and subjected to RT-PCR or West-
ern blotting, respectively. B: Western blot of Fra-1 in cells pretreated with indomethacin (10   M) for 30 min 
prior to AA (100   M) treatment for 24 h. C: Cells were treated for 24 h with PGF 2   (10 nM) and total RNA 
(left panel) or whole cell lysates (right panel, 24 h) were harvested at the indicated time points and subjected 
to RT-PCR or Western blotting, respectively. D: Cells were pretreated with AL 8810 (10   M) for 30 min 
prior to AA (100   M) for 24 h. Total RNA was extracted and subjected to RT-PCR for Fra-1 mRNA tran-
script. E: 80% confl uent 3T3-L1 cells were transfected with siControl or siFP. On the third day after transfec-
tion, cells were treated with 100   M AA for 24 h in the presence of MDI. Western blot was performed with 
antibodies against Fra-1 and GAPDH. F, G: Cells were pretreated with GF109203X (10   M) or U0126 
(10   M) for 30 min prior to AA (100   M) stimulation for 24 h. Western blot was performed using antibodies 
against Fra-1 and GAPDH. Fra-1 mRNA levels are presented as fold change of the vehicle control from n = 3. 
Error bars represent ±SEM. ** P < 0.01, *** P < 0.001. 
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 Fig.  6. Fra-1 mediates the inhibition of adipocyte differentiation by AA. A: 3T3-L1 cells were treated with increasing doses of AA for 24 h 
in the presence of MDI. After the 24 h, AA was withdrawn and total RNA was isolated on day 10 of the differentiation and subjected to RT-
PCR for aP2, PPAR  2, and C/EBP  . Data are presented as mean ± SEM based on triplicate determinations. * P < 0.05, ** P < 0.01, *** P < 
0.001. B: As above, but cells were treated with increasing doses of PGF 2   . C: Eighty percent confl uent 3T3-L1 cells were transfected with 
either siFra-1 or siControl. On the third day of transfection, cells were treated with 500   M AA for 24 h in the presence of MDI. The next 
day, AA was withdrawn and the differentiation protocol continued until day 10. Cells were fi xed and stained with Oil Red O and pictures 
were captured under a light microscope (20× magnifi cation). D: Cells were transfected and treated as described in (C). Total RNA was 
isolated on day 10 and RT-PCR was performed. Data are presented as mean ± SEM of n = 3. A Student’s  t -test was performed for BSA and 
AA-treated siControl (a:  P < 0.001, d:  P < 0.05) and for AA-treated siControl and siFra-1 (b:  P < 0.001, c:  P < 0.05). 
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context of adipogenesis, sustained ERK activation can in-
hibit differentiation ( 47 ). Our data suggest that the sus-
tained ERK activation by AA in preadipocytes leads to the 
upregulation of aP2 and Fra-1 expression. 
 AA itself, but also 15-deoxy-  12,14 PGJ 2 , have been de-
scribed to be direct ligands for PPAR  ( 13–15 ), making 
AA a good candidate for regulating adipogenesis. How-
ever, in vitro cell models yielded different results, showing 
AA to act both pro-adipogenically and anti-adipogenically 
( 5–10 ). Animal feeding studies showed the same confl ict-
ing results ( 6, 7 ), and a similar scenario was also observed 
in studies of COX-2 ( 53, 54 ). However, it has been pro-
posed that cAMP levels govern the action of AA on adipo-
genesis ( 10 ). Our results reveal that Fra-1 upregulation by 
AA in preadipocytes is the key event in the mechanism by 
which short-term exposure to AA can program the differ-
entiation potential of preadipocytes. Thus, the diversity 
found in different cell and animal models could lie in the 
different Fra-1 expression levels likely to be governed by 
ERK activation, a strong Fra-1 regulator. In addition, our 
observations are in agreement with in vivo data, as deplet-
ing Fra-1 in 3T3-L1 cells does not perturb differentiation 
(this study) in accord with normal adipose tissue observed 
in Fra-1 knockout mice ( 55 ). A defect is apparent when 
Fra-1 is overexpressed, as it appears to act as a brake on the 
differentiation procedure, inasmuch as Fra-1 transgenic 
mice become lipodystrophic ( 30 ). However, the mecha-
nism by which Fra-1 can cause the inhibition of differentia-
tion still remains to be determined. It has been shown that 
PGF 2  , via ERK activation, can inhibit PPAR  activity ( 44 ), 
raising the possibility that Fra-1 is acting through PPAR  , 
as shown for Fra-2 ( 56 ). It is possible that early in differen-
tiation, AA could modulate PPAR  activity by phosphory-
lation via the production of PGF 2   , which in turn can 
decrease the transcriptional activity of PPAR  , inhibiting 
future maturation. In addition, new data suggest that aP2 
can also inhibit adipocyte differentiation by downregulat-
ing PPAR  ( 57 ). Thus, our study suggests that upregula-
tion of both aP2 and Fra-1, in response to AA, inhibits 
adipogenesis and highlights their increasingly evident im-
portance in adipocyte differentiation ( 56, 57 ). 
 In conclusion, this is the fi rst report showing that AA, 
through PGF 2   signaling, regulates aP2 and Fra-1 expres-
sion at the early stages of preadipocyte differentiation. We 
demonstrate that Fra-1 upregulation at the early stages 
causes the inhibition of adipocyte differentiation by AA, 
opening new possibilities to manage diet-induced obesity.  
 The authors would like to thank Dr. Asmaà Fritah, Dr. Ariel 
Poliandri, and Dr. Alexandra Milona for the valuable comments 
on this work. 
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